AACC uses cookies to ensure the best website experience. Continuing without changing cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


Features


New guidance from AACC on serology testing and SARS-CoV-2 will help clinical laboratories and clinicians utilize and interpret these assays. From orthogonal testing approaches to clinical case studies, AACC experts explain how health systems can use antibody tests for the numerous patient scenarios clinicians are facing.
Historically, clinical laboratories have referred to reference intervals (RI) as normal ranges and developed them using samples from a “normal or healthy” population. This approach to RI quickly encounters a stumbling block, however. Namely: How do we define who is normal?
Even with growing evidence, it has been a struggle for clinical laboratorians to identify and properly use biomarkers for preterm delivery. Now, new recommendations seek to clarify which biomarkers are truly useful and when, which in some cases may lead to laboratories to retiring tests, and in others, developing new…

Ask the Expert


Expert Christopher G. Suciu, MD, discusses the ins and outs of radioactive patient samples—what the types of radioactive samples are that labs have to handle, whether or not these samples pose a risk to laboratory staff, and recommendations labs should follow when processing these samples.

Bench Matters


Federal Insider


Senator Rand Paul of Kentucky has reintroduced the VITAL Act, which would formally place LDT regulation solely under CLIA and separate it from Food and Drug Administration oversight. AACC has endorsed the bill.

Industry Playbook


Laboratory Stewardship


Regulatory Roundup


The Sample